A mathematical model of venous neointimal hyperplasia formation

BackgroundIn hemodialysis patients, the most common cause of vascular access failure is neointimal hyperplasia of vascular smooth muscle cells at the venous anastomosis of arteriovenous fistulas and grafts. The release of growth factors due to surgical injury, oxidative stress and turbulent flow has been suggested as a possible mechanism for neointimal hyperplasia.ResultsIn this work, we construct a mathematical model which analyzes the role that growth factors might play in the stenosis at the venous anastomosis. The model consists of a system of partial differential equations describing the influence of oxidative stress and turbulent flow on growth factors, the interaction among growth factors, smooth muscle cells, and extracellular matrix, and the subsequent effect on the stenosis at the venous anastomosis, which, in turn, affects the level of oxidative stress and degree of turbulent flow. Computer simulations suggest that our model can be used to predict access stenosis as a function of the initial concentration of the growth factors inside the intimal-luminal space.ConclusionThe proposed model describes the formation of venous neointimal hyperplasia, based on pathogenic mechanisms. The results suggest that interventions aimed at specific growth factors may be successful in prolonging the life of the vascular access, while reducing the costs of vascular access maintenance. The model may also provide indication of when invasive access surveillance to repair stenosis should be undertaken.

[1]  Y. Miyachi,et al.  Expression of basic fibroblast growth factor and its receptor by fibroblast, macrophages and mast cells in hypertrophic scar. , 1999, European journal of dermatology : EJD.

[2]  Prabir Roy-Chaudhury,et al.  Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  G. Heine,et al.  Is AV Fistula Patency Associated with Angiotensin-Converting Enzyme (ACE) Polymorphism and ACE Inhibitor Intake? , 2004, American Journal of Nephrology.

[4]  T. Dix,et al.  Redox-mediated activation of latent transforming growth factor-beta 1. , 1996, Molecular endocrinology.

[5]  P. Singhal,et al.  Leukocyte-polytetrafluoroethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-alpha secretion. , 1997, Kidney international.

[6]  G. Heine,et al.  Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. , 2003, Kidney international.

[7]  David R. Brown Dependence of Neurones on Astrocytes in a Coculture System Renders Neurones Sensitive to Transforming Growth Factor \gb\1‐Induced Glutamate Toxicity , 1999, Journal of neurochemistry.

[8]  L O,et al.  A Mechanochemical Model for Adult Dermal Wound Contraction and the Permanence of the Contracted Tissue Displacement Profile , 1995 .

[9]  R. Friedl,et al.  Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. , 2002, Kidney international.

[10]  M. Robbin,et al.  Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. , 2002, Kidney international.

[11]  H. Feldman,et al.  Hemodialysis vascular access morbidity. , 1996, Journal of the American Society of Nephrology : JASN.

[12]  L. Antiga,et al.  Radial artery wall shear stress evaluation in patients with arteriovenous fistula for hemodialysis access. , 2003, Biorheology.

[13]  M. Karkkainen,et al.  The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man* , 2001, The Journal of Biological Chemistry.

[14]  G. Poli,et al.  The lipid peroxidation end product 4‐hydroxy‐2,3‐nonenal up‐regulates transforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  M. Raftery,et al.  Does the arteriovenous fistula in chronic haemodialysis patients stimulate endothelin-1 release? , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  E. Woodcock,et al.  A LOW AFFINITY, LOW MOLECULAR WEIGHT ENDOTHELIN‐A RECEPTOR PRESENT IN NEONATAL RAT HEART , 1993, Clinical and experimental pharmacology & physiology.

[17]  Gary R. Grotendorst Chemoattractants and growth factors , 1992 .

[18]  B. G. Brown,et al.  Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. , 1989, Circulation.

[19]  M. Daemen,et al.  Intimal hyperplasia in vascular grafts. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[20]  M. F. Weiss,et al.  Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  T. Masaki,et al.  Pathophysiology of endothelin in the cardiovascular system. , 1999, Annual review of physiology.

[22]  I. K. Cohen,et al.  Wound Healing: Biochemical & Clinical Aspects , 1992 .

[23]  R. Moritz,et al.  Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing Which Generates Non-covalent Homodimers* , 1999, The Journal of Biological Chemistry.

[24]  D. Windus Permanent vascular access: a nephrologist's view. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[26]  C. Hehrlein How do AV fistulae lose function? The roles of haemodynamics, vascular remodelling, and intimal hyperplasia. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  K. Porter,et al.  Endothelin‐1 is a mediator of intimal hyperplasia in organ culture of human saphenous vein , 1997, The British journal of surgery.

[28]  K. Kent,et al.  The effect of growth factors, cytokines, and extracellular matrix proteins on fibronectin production in human vascular smooth muscle cells. , 2000, Journal of vascular surgery.

[29]  David Roth,et al.  Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. , 2005, Kidney international.

[30]  S. Heffelfinger,et al.  Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. , 2001, Kidney international.

[31]  V. Sukhatme,et al.  Vascular access stenosis: prospects for prevention and therapy. , 1996, Kidney international.

[32]  W. Border,et al.  Transforming Growth Factor β in Tissue Fibrosis , 1994 .

[33]  E C Nice,et al.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3 , 2001, The EMBO journal.

[34]  A. Dardik,et al.  Arterial Wall Shear Stress: Observations from the Bench to the Bedside , 2003, Vascular and endovascular surgery.

[35]  M. Aviram LDL-Platelet Interaction Under Oxidative Stress Induces Macrophage Foam Cell Formation , 1995, Thrombosis and Haemostasis.

[36]  J A Sherratt,et al.  A mechanochemical model for adult dermal wound contraction and the permanence of the contracted tissue displacement profile. , 1995, Journal of theoretical biology.

[37]  W. Border,et al.  Transforming growth factor beta in tissue fibrosis. , 1994, The New England journal of medicine.